Clovis Oncology reported a GAAP loss of $60.169 million for the 3 months of 2022, down 9.2% from $66.277 million in the prior year. Revenue decreased 10% to $34.247 million from $38.053 million a year earlier.
Clovis Oncology reported a GAAP loss of $60.169 million for the 3 months of 2022, down 9.2% from $66.277 million in the prior year. Revenue decreased 10% to $34.247 million from $38.053 million a year earlier. 
ir.clovisoncology.com
English (US) 